Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor.
Ketoconazole (KTZ) has been used as a second-line agent in hormone-refractory cancer therapy. Since transition metal complexes including those of Ru(III), show important anticancer activity with limited toxicity, we investigated the potential antitumor efficacy of Ru(II) complexed to KTZ or clotrimazole (CTZ) compared to Ru(II) alone or uncomplexed azoles. RuCl2(KTZ)2 exerted greater apoptosis- associated caspase-3 activation than RuCl2(CTZ)2, KTZ, CTZ or RuCl2(MeCN)4 against several human tumor cell monolayers. PARP cleavage and a decrease in S+G2 cells were evident after RuCl2(KTZ)2 treatment in genetically matched C8161 melanoma monolayers with unequal p53 functional status. Release of mitochondrial cytochrome c and Mn-SOD suggest mitochondria as a target of RuCl2(KTZ)2. Treatment of WM164 melanoma monolayers with 25 microM of cisplatin or RuCl2(KTZ)2 showed that the latter is more effective than cisplatin at inducing PARP fragmentation and proapoptotic Bak expression. Such results suggest that these Ru(II) and Pt(II) metal complexes are unequally effective and act through alternative signaling pathways. In studies with multicellular spheroids, which frequently are more resistant to cytotoxic anticancer drugs than monolayers, those from wt p53 C8161 melanoma underwent PARP fragmentation in response to RuCl2(KTZ)2. In contrast, spheroids of mut p53 A431 carcinoma overexpressing EGF receptor were resistant to either RuCl2(KTZ)2 or anti-EGF receptor C225 MAb. However, joint treatment with both agents restored growth arrest and apoptosis in these spheroids. In contrast to the antitumor action of cisplatin, which is known to be hampered by p53 dysfunction, we show that RuCl2(KTZ)2 is active irrespective of p53 functional status against several adherent tumor cells and synergizes with anti-EGF receptor C225 MAb to kill tumor spheroids resistant to either agent.
Strasberg Rieber
Mary
M
Laboratory of Tumor Cell Biology, CMBC, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela.
Anzellotti
Atilio
A
Sánchez-Delgado
Roberto A
RA
Rieber
Manuel
M
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D002945:Cisplatin / Q000008:administration & dosage; D003022:Clotrimazole / Q000008:administration & dosage; D003131:Combined Modality Therapy; D045304:Cytochromes c / Q000378:metabolism; D004357:Drug Synergism; D004789:Enzyme Activation / Q000187:drug effects; D066246:ErbB Receptors / Q000276:immunology*; D006801:Humans; D007654:Ketoconazole / Q000008:administration & dosage; D008565:Membrane Proteins / Q000378:metabolism; D008928:Mitochondria / Q000187:drug effects; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology*; D011065:Poly(ADP-ribose) Polymerases; D017975:Ruthenium Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D018874:Spheroids, Cellular / Q000473:pathology; D013482:Superoxide Dismutase / Q000378:metabolism; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D050998:bcl-2 Homologous Antagonist-Killer Protein
D000911:Antibodies, Monoclonal; C494772:BAK1 protein, human; D008565:Membrane Proteins; D017975:Ruthenium Compounds; D016159:Tumor Suppressor Protein p53; D050998:bcl-2 Homologous Antagonist-Killer Protein; D045304:Cytochromes c; D013482:Superoxide Dismutase; D011065:Poly(ADP-ribose) Polymerases; D066246:ErbB Receptors; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases; D003022:Clotrimazole; D002945:Cisplatin; D007654:Ketoconazole; C038365:ruthenium chloride